

19. The protein of claim 18, wherein the Tet repressor is a Tn10-derived Tet repressor.
20. The protein of claim 18, wherein the second polypeptide comprises a transcription activation domain of herpes simplex virion protein 16.
21. The protein of claim 19, wherein the second polypeptide comprises the C-terminal 130 amino acids of herpes simplex virion protein 16.
22. The protein of claim 18, wherein the second polypeptide comprises a transcription activation domain selected from the group consisting of an acidic transcription activation domain, a proline-rich transcription activation domain, a serine/threonine-rich transcription activation domain and a glutamine-rich transcription activation domain.--

#### REMARKS

Claim 1 was originally filed in the application. New claims 18-22 have been added. Accordingly, claims 1 and 18-22 are pending.

The title has been amended to more accurately reflect the subject being claimed in the application. The specification also has been amended to correct a number of minor informalities. New claims 18-22 are directed to transcriptional activator fusion proteins. Support for these claims can be found in the specification at, for example, pages 24, line 22 through page 26, line 1 and in Example 1 (pages 41-49).


No new matter has been added by way of the amendments to the specification or the new claims. Applicants respectfully request that these amendments be entered.

#### SUMMARY

All pending claims are believed to be in condition for allowance. If a telephone conversation with Applicants' Agent would expedite the prosecution of the above-

identified application, the examiner is urged to call Applicants' Agent at (617) 227-7400.

Respectfully submitted,



Catherine J. Kara, Ph.D.

Registration No. 41,106

Agent for Applicants

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, MA 02109

Tel. (617) 227-7400

Dated: September 29, 1998